Novel tricyclic heterocyclic carbaldehyde compound and pharmaceutical composition for inhibiting IRE1[alpha] including the same

The present disclosure relates to a novel tricyclic heterocyclic carbaldehyde compound and a pharmaceutical composition for inhibiting inositol requiring enzyme 1[alpha] (IRE1[alpha]) including the same. More specifically, the present disclosure relates to a novel tricyclic heterocyclic carbaldehyde...

Full description

Saved in:
Bibliographic Details
Main Authors JUNG, SEUNG-HYUN, KIM, JI-SOOK, KIM, MIN-JEONG, CHOI, JAE-YUL, AHN, YOUNG-GIL, PARK, WON-GI
Format Patent
LanguageChinese
English
Published 16.04.2024
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present disclosure relates to a novel tricyclic heterocyclic carbaldehyde compound and a pharmaceutical composition for inhibiting inositol requiring enzyme 1[alpha] (IRE1[alpha]) including the same. More specifically, the present disclosure relates to a novel tricyclic heterocyclic carbaldehyde compound for treating or preventing IRE1[alpha]-associated diseases and a pharmaceutical composition including the same.
Bibliography:Application Number: TW202312137253